Omega 3 Supplementation for the Prevention of Disease Progression in Early Stage Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM)
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 11/23/2013 |
| Start Date: | August 2008 |
| End Date: | July 2012 |
| Contact: | Leann R Ross, RN |
| Email: | leann.ross@chhi.org |
| Phone: | 304-399-6617 |
Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies
Escalating doses of Omega 3 Fatty Acids are being used in patients who have early stage
Chronic Lymphocytic Leukemia (ES-CLL), Monoclonal Gammopathy of Undetermined Significance
(MGUS), or Smoldering Multiple Myeloma (SMM), whose disease does not currently require
treatment. The primary aim of the study is to determine if the Omega 3 supplementation will
help prevent or delay progression of the disease to a stage that requires treatment.
Inclusion Criteria:
- Must be over 18 years of age.
- Must be free of other medical conditions that would decrease life expectancy to less
that 12 months.
- Must be free of Omega 3 supplements or other fish oil containing nutritional
supplements for a minimum of two months prior to enrollment.
- Must have a ECOG performance status of 0,1 or 2.
Exclusion Criteria:
- Any life-threatening condition such as (but not limited to) advanced heart disease,
kidney or liver failure with an expected survival of less than 12 months.
- Any other active malignancy.
- Women who are pregnant or lactating.
- Individuals unable to give informed consent.
- Individuals with known allergy or intolerance to fish oil supplements.
- Any patient with an active bleeding diatheses or disorder.
- ECOG performance status of 3 or 4.
We found this trial at
1
site
Click here to add this to my saved trials
